Literature DB >> 11926410

Tumour escape from immune surveillance through dendritic cell inactivation.

Alain P Vicari1, Christophe Caux, Giorgio Trinchieri.   

Abstract

Dendritic cells (DC) are central to the initiation of immunity. To induce immune reactivity, DC are recruited at the site of antigen expression, uptake antigens and migrate to secondary lymphoid organs while receiving activation signals delivered by pathogens, dying cells, and/or T cells. Tumours can escape the immune system by interfering with the migration of DC or by not providing the necessary activation signals. Moreover, tumours promote the secretion of factors that inhibit DC differentiation and functions. We will review the current knowledge of the physiopathology of DC in cancer, which paves the way for novel strategies of therapeutic intervention.

Entities:  

Mesh:

Year:  2002        PMID: 11926410     DOI: 10.1006/scbi.2001.0400

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  59 in total

1.  Langerhans cells from human cutaneous squamous cell carcinoma induce strong type 1 immunity.

Authors:  Hideki Fujita; Mayte Suárez-Fariñas; Hiroshi Mitsui; Juana Gonzalez; Mark J Bluth; Shali Zhang; Diane Felsen; James G Krueger; John A Carucci
Journal:  J Invest Dermatol       Date:  2012-03-08       Impact factor: 8.551

2.  Specifically activated dendritic cells--cell-based vaccine against lymphosarcoma exhibiting multiple drug resistance phenotype.

Authors:  N L Mironova; E E Panzinskyi; N A Popova; V P Nikolin; M A Zenkova; V V Vlasov
Journal:  Dokl Biochem Biophys       Date:  2009 Sep-Oct       Impact factor: 0.788

3.  Fine-tuning anti-tumor immunotherapies via stochastic simulations.

Authors:  Giulio Caravagna; Roberto Barbuti; Alberto d'Onofrio
Journal:  BMC Bioinformatics       Date:  2012-03-28       Impact factor: 3.169

4.  Loss of the innate immunity negative regulator IRAK-M leads to enhanced host immune defense against tumor growth.

Authors:  Qifa Xie; Lu Gan; Jianxia Wang; Ingred Wilson; Liwu Li
Journal:  Mol Immunol       Date:  2007-05-02       Impact factor: 4.407

5.  Radiation and immunotherapy: a synergistic combination.

Authors:  Anusha Kalbasi; Carl H June; Naomi Haas; Neha Vapiwala
Journal:  J Clin Invest       Date:  2013-07-01       Impact factor: 14.808

6.  Sialyl Tn-expressing bladder cancer cells induce a tolerogenic phenotype in innate and adaptive immune cells.

Authors:  Mylène A Carrascal; Paulo F Severino; M Guadalupe Cabral; Mariana Silva; José Alexandre Ferreira; Fernando Calais; Hermínia Quinto; Cláudia Pen; Dário Ligeiro; Lúcio Lara Santos; Fabio Dall'Olio; Paula A Videira
Journal:  Mol Oncol       Date:  2014-03-06       Impact factor: 6.603

7.  Retrospective chart review of skin cancer presence in the wide excisions.

Authors:  Ye Yuan; Michelle L Duff; Dawn L Sammons; Shiyong Wu
Journal:  World J Clin Cases       Date:  2014-03-16       Impact factor: 1.337

8.  Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation.

Authors:  C Andrew Stewart; Hannah Metheny; Noriho Iida; Loretta Smith; Miranda Hanson; Folkert Steinhagen; Robert M Leighty; Axel Roers; Christopher L Karp; Werner Müller; Giorgio Trinchieri
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

9.  Accumulation of tolerogenic human 6-sulfo LacNAc dendritic cells in renal cell carcinoma is associated with poor prognosis.

Authors:  Marieta Toma; Rebekka Wehner; Anja Kloß; Linda Hübner; Georgia Fodelianaki; Kati Erdmann; Susanne Füssel; Stefan Zastrow; Matthias Meinhardt; Barbara Seliger; Dorothee Brech; Elfriede Noessner; Torsten Tonn; Knut Schäkel; Martin Bornhäuser; Michael P Bachmann; Manfred P Wirth; Gustavo Baretton; Marc Schmitz
Journal:  Oncoimmunology       Date:  2015-03-02       Impact factor: 8.110

10.  Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-Like Receptor agonists as a treatment for melanoma.

Authors:  Geoffrey W Stone; Suzanne Barzee; Victoria Snarsky; Camila Santucci; Brian Tran; Robert Langer; Gregory T Zugates; Daniel G Anderson; Richard S Kornbluth
Journal:  PLoS One       Date:  2009-10-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.